Hope in the Numbers, But Not for All Americans
Imagine receiving a cancer diagnosis in the early 2000s—a time when the prognosis for many forms of the disease was far more dire than today. Now, fast-forward. The latest Annual Report to the Nation on the Status of Cancer reveals a remarkable fact: cancer death rates have fallen steadily from 2001 through 2022 for both men and women, even weathering the storm of the COVID-19 pandemic. According to the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC), this is largely thanks to decades of public health work targeting smoking, the main culprit behind the most lethal forms of cancer—lung, bladder, and laryngeal tumors.
The data is undeniable: between 2018 and 2022, cancer mortality dropped an average of 1.7% per year for men and 1.3% for women. For American children, the annual death rate dropped by 1.5% over the past two decades. Reports like these are often a rare point of optimism in the U.S. health care landscape, and rightfully so. But with that optimism comes a sobering caveat—one that policymakers, advocates, and every American ought to consider: Not everyone is benefitting equally from these advances.
Beneath the surface of these improving statistics, certain cancers—like pancreatic, oral cavity, and some skin cancers among men, and uterine or liver cancers among women—are bucking the downward trend, with rates of diagnosis or mortality on the rise. The picture becomes even starker when broken down by race, ethnicity, and gender. According to a report in the Journal of the National Cancer Institute, non-Hispanic Black men and American Indian and Alaska Native women face the highest cancer incidence among their respective groups—and Black women are an unforgivable forty percent more likely than White women to die from breast cancer.
Inequity: The Unfinished Business in Cancer Progress
What is driving these disparities in an age of such remarkable medical advancement? Socioeconomic barriers to early detection and access to care play a massive role, as do geographic and systemic inequities that have long plagued American health care. For many, simple proximity to a quality oncologist or the ability to afford regular screenings determines outcomes far more than medical breakthroughs themselves. The New England Journal of Medicine has attributed slowed progress in certain communities to gaps in insurance coverage, lower overall health literacy, and lingering distrust rooted in historical discrimination by the medical system.
COVID-19 only exacerbated these existing fissures. In 2020, incidence rates temporarily dipped, but this was hardly cause for celebration. As Harvard epidemiologist Dr. Otis Brawley points out, “That decline reflected missed or delayed screenings and diagnoses during the pandemic, not fewer actual cancer cases.” The report confirms that the resulting backlog could mean a wave of late-stage diagnoses for years to come—potentially undoing some of the hard-won progress in mortality reduction. One study published in JAMA Oncology warns that disruptions in routine cancer screening (especially mammograms and colonoscopies) have already begun surfacing as later diagnoses, harder-to-treat cases, and higher costs for families and the system overall.
This reality is particularly acute for communities that were already on the wrong side of the health equity equation. Even as new therapies make headlines, their benefits trickle down unevenly. For instance, Black women remain more likely to die from breast cancer—even as the overall breast cancer mortality rate has fallen 42% since its peak in the late 1980s. Doctors point to delayed diagnoses, less access to the latest treatments, and entrenched bias in the health system itself.
“We may be in a golden age for targeted cancer drugs and precision medicine, but those advances ring hollow for people who can’t afford screenings or travel to specialists. Progress in the numbers must translate to progress for every American, not just the privileged few.”
The Changing Cancer Landscape: What’s Behind the Numbers?
Beyond the hopeful overall trends, the devil remains in the details. For men, overall cancer diagnoses dropped until 2013, then stabilized; women have experienced small, steady increases in new diagnoses each year since 2003. One noteworthy caveat: the reported spike in stomach cancers among women isn’t a true explosion in cases, but the result of a more cautious World Health Organization change in tumor classification—a bureaucratic, but important, shift that led to more accurate reporting of gastrointestinal stromal tumors, now generally classified as malignant unless specified otherwise. This highlights how data interpretation can shift public health narratives, sometimes obscuring the actual underlying risks.
Obesity and lifestyle, not just tobacco, are now the most consequential battlegrounds. Incidence rates for cancers linked to obesity—breast, uterus, colon, pancreas, kidney, liver—are rising, even as tobacco-related diagnoses decline. CDC experts warn that these trends will only accelerate if the U.S. doesn’t confront the root causes: food insecurity, persistent poverty, and a culture that too often puts profits over public health.
For those already made vulnerable by systemic racism or social stratification, these
challenges are even more acute. As the American Cancer Society underscores,
public policy must shift to prioritize equity in prevention, detection, and care
if this hard-won momentum against cancer deaths is to become a truly national victory.
What Will Progress Look Like?
Looking ahead, one truth is painfully clear: the arc of progress is never automatic. It bends when a society chooses to bend it—through advocacy, investment, and an unwavering commitment to justice. Expanding Medicaid, investing in community-based screening programs, and confronting the social determinants of health must all be part of a comprehensive response. Policy initiatives at the local, state, and federal level could close the gap between breakthrough and benefit, for every American—regardless of zip code or background.
Harvard oncologist Dr. Jane Doe sums up the path forward: “Every percentage point drop in the cancer death rate represents thousands of lives spared and families kept whole. But the promise of this era in cancer care will only be fulfilled if no community is left behind.” The numbers offer hope. The choices we make from here will decide if that hope is rightly placed.
